BNP Paribas Bonus Zert NVSEF 26.0.../ DE000PC1U5M7 /
5/15/2024 10:18:14 AM | Chg.- | Bid10:00:39 PM | Ask10:00:39 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
96.14EUR | - | - Bid Size: - |
- Ask Size: - |
Novartis AG | - - | 9/26/2024 | Call |
GlobeNewswire
6/13
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
GlobeNewswire
6/13
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Director...
GlobeNewswire
6/13
American Kidney Fund Convenes Rare Kidney Disease Action Network to Advocate for Policies and Regula...
GlobeNewswire
6/13
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
4/16
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
3/14
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
2/28
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
1/10
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
1/5
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire
1/2
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire
12/21/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
12/19/2023
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...